Precision BioSciences stock gets DMD dosing clearance after safety review
Published on 11/19/2026 at 01:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDMD Trial Advances After Review
- An independent safety board found no safety concerns after the first patient's eight-week observation period.
- The board endorsed dosing additional patients in Part 1 of the FUNCTION-DMD study.
- Precision is developing PBGENE-DMD to restore near full-length dystrophin through targeted gene editing.
Precision BioSciences said on November 5 that an independent Data Safety Monitoring Board had cleared additional dosing in the Phase 1/2 FUNCTION-DMD trial after reviewing the first patient's safety record. The company said no serious adverse events or adverse events of special interest had been reported through week eight. The announcement was published by Precision BioSciences.
Safety Review Clears Further Dosing
The DSMB endorsed proceeding with additional patients in Part 1 of FUNCTION-DMD after the initial eight-week observation period. Precision said the study is enrolling ambulatory boys aged 2 to 7 with Duchenne muscular dystrophy and mutations between exons 45 and 55.
PBGENE-DMD uses two ARCUS nucleases delivered in a single adeno-associated virus to excise exons 45 to 55 of the dystrophin gene. The company aims to restore a near full-length functional dystrophin protein rather than use a truncated microdystrophin approach.
Clinical Milestones Remain Ahead
Precision said safety and efficacy updates from FUNCTION-DMD are expected throughout 2027. The trial is designed to assess safety, tolerability and efficacy, including dystrophin protein expression and functional outcomes.
Precision BioSciences Company Profile
Precision BioSciences is a United States clinical-stage biotechnology company focused on genome editing. Its proprietary ARCUS platform is designed for therapeutic gene correction and is being used to develop in vivo treatments for cancer and infectious diseases. The company is advancing programs that use gene elimination, gene excision and gene insertion to address diseases with limited treatment options.
Precision BioSciences at a Glance
- Company: Precision BioSciences, Inc.
- ISIN: US74019P2074
- Ticker: DTIL
- Home exchange: Nasdaq Capital Market
- Headquarters: Durham, North Carolina, United States
- Sector: Biotechnology
The broader US market context is covered in current market reports.
